Home

The Korea Herald

Latest news

Most Popular

  1. 1

    Contentious grain bill put directly to plenary meeting for vote

    Contentious grain bill put directly to plenary meeting for vote
  2. 2

    Yoon's approval rating plunges to all-time low

    Yoon's approval rating plunges to all-time low
  3. 3

    Will tug-of-war between doctors, government end soon?

    Will tug-of-war between doctors, government end soon?
  4. 4

    Climate impacts set to cut 2050 global GDP by nearly a fifth

    Climate impacts set to cut 2050 global GDP by nearly a fifth
  5. 5

    Trilateral talks acknowledge ‘serious’ slumps of won, yen

    Trilateral talks acknowledge ‘serious’ slumps of won, yen
  1. 6

    [KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs

    [KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs
  2. 7

    North Korea removes streetlights along cross-border roads with South

    North Korea removes streetlights along cross-border roads with South
  3. 8

    Russia's denial of entry of S. Korean national unrelated to bilateral ties: Seoul official

    Russia's denial of entry of S. Korean national unrelated to bilateral ties: Seoul official
  4. 9

    Farming households dip below 1m for first time in 2023

    Farming households dip below 1m for first time in 2023
  5. 10

    S. Korea votes in favor of Palestinian bid for UN membership

    S. Korea votes in favor of Palestinian bid for UN membership
지나쌤

Samsung Bioepis wins approval to sell biosimilar in South Korea

By Jo He-rim

Published : Sept. 20, 2017 - 20:54

    • Link copied

Samsung Biologics Co. said Wednesday its affiliate Samsung Bioepis Co. won a nod from South Korea‘s drug agency to sell its biosimilar dubbed SB5.

Through the approval granted by the Ministry of Food and Drug Safety, Samsung Biologics said in a regulatory filing that the biosimilar is ready for sale in the country.

Ko Han-sung, CEO of Samsung Bioepis Ko Han-sung, CEO of Samsung Bioepis

The SB5 is a biosimilar of Humira released by U.S.-based AbbVie Inc., used for the treatment of various diseases including Crohn’s disease and rheumatoid arthritis.

A biosimilar is a copy of a medicine developed after the patents for the original drug have expired.

Samsung Biologics said the detailed launch schedule of the biosimilar will be fixed later to reflect the patent expiration date of Humira.

Samsung Bioepis is a joint venture between Samsung Biologics and U.S. Biogen Inc.

More from Headlines